The HSA approved the Cue Covid-19 test for self-testing through its Pandemic Special Access Route (PSAR). Image Representative. Credit: Hermann Kollinger / Pixabay.

The Health Sciences Authority (HSA) in Singapore has authorised the use of Cue Health’s molecular Covid-19 test for self-testing.

The Cue Covid-19 test for self-testing was approved by the HSA through its Pandemic Special Access Route (PSAR).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With the authorisation, the test can now be used at home to detect infection in both symptomatic and asymptomatic individuals above two years of age.

Cue Health has already partnered with local company Omnicell to begin immediately supplying the Cue Covid-19 Test in Singapore.

Omnicell regional account director Yoco Ting said: “Testing remains an important component in Singapore’s overall strategy for managing Covid-19.

“With the recent authorisation of the Cue Covid-19 Test via the PSAR, Omnicell is excited to bring forth into Singapore the technological advancement from Cue and further simplify the Covid-19 testing process by now combining the speed of rapid antigen tests with the lab-quality accuracy of PCR tests.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We will continue to work closely with local authorities and Cue to further the effort in controlling Covid-19 in Singapore.”

Cue Health is a healthcare technology company headquartered in San Diego, California, US.

Last month, the company introduced its direct-to-consumer (DTC) virtual health platform in the US. The move made its molecular Covid-19 test available through the company’s new eCommerce site and in-app shop.

Commenting on the approval in Singapore, Cue co-founder and CEO Ayub Khattak said: “We are excited to bring Cue’s digitally connected, in-home molecular diagnostics platform to Singaporean stakeholders and help provide immediate access to critical health information.

“With Cue, users will be able to make faster and more informed healthcare decisions at a time when it’s needed most.”

In February, Cue received CE mark for its molecular point-of-care Covid-19 test in the European Union (EU).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact